---
title: "Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290970667.md"
description: "William Blair analyst Myles Minter reiterated a Hold rating on Moderna (MRNA), citing its industry-leading mRNA platform balanced against early-stage pipeline risks. While acknowledging strong manufacturing capabilities and cost efficiencies, the neutral stance reflects uncertainty regarding clinical maturity of key programs. Citi also maintained a Hold rating with a $41 price target."
datetime: "2026-06-26T13:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290970667.md)
  - [en](https://longbridge.com/en/news/290970667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290970667.md)
---

# Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks

William Blair analyst Myles Minter has reiterated their neutral stance on MRNA stock, giving a Hold rating today.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Myles Minter has given his Hold rating due to a combination of factors that balance Moderna’s strong platform with its execution risks. He views the company’s mRNA technology and manufacturing capabilities as industry-leading, with clear advantages in cost efficiency and the ability to design complex, multiplexed products across oncology and autoimmune indications.

At the same time, much of the value lies in early-stage programs that still need to mature clinically, which tempers near-term visibility and justifies a more neutral stance. While management’s disciplined capital allocation and faster-than-expected cost reductions are encouraging, the dependence on proof-of-concept success from “sentinel” assets and subsequent expansion introduces uncertainty that, in his view, warrants maintaining a Hold rather than a more aggressive rating.

In another report released today, Citi also maintained a Hold rating on the stock with a $41.00 price target.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [Moderna’s mRNA flu vaccine passes FDA AdCom, review underway](https://longbridge.com/en/news/290435765.md)
- [Moderna publishes Science Day 2026 presentation](https://longbridge.com/en/news/290839905.md)